We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Avacincaptad Pegol: First Approval.
- Authors
Kang, Connie
- Abstract
Avacincaptad pegol (IZERVAY™; formerly Zimura®) is a complement C5 inhibitor that is being developed by IVERIC Bio, an Astellas company, for the treatment of geographic atrophy secondary to age-related macular degeneration. Avacincaptad pegol recently received approval for the treatment of adults with geographic atrophy secondary to age-related macular degeneration. This article summarizes the milestones in the development of avacincaptad pegol leading to this first approval for geographic atrophy secondary to age-related macular degeneration.
- Subjects
UNITED States; DRUG approval; RETINAL degeneration; CLINICAL trials; IMMUNOSUPPRESSIVE agents; PATIENT safety; PHARMACODYNAMICS
- Publication
Drugs, 2023, Vol 83, Issue 15, p1447
- ISSN
0012-6667
- Publication type
Article
- DOI
10.1007/s40265-023-01948-8